Money

Novo Nordisk Seeks FDA Approval for Higher-Dose Weight Management Drug

Novo Nordisk recently took a significant step in expanding its chronic weight management treatment portfolio by submitting a supplemental marketing application to the U.S. Food and Drug Administration (FDA). This application seeks approval for a new, higher dose of its semaglutide injection, Wegovy, specifically 7.2 mg, building on the success of its existing 2.4 mg formulation.

This initiative follows a parallel review process in Europe, where the European Medicines Agency, along with regulatory bodies in the U.K. and other countries, is already evaluating the 7.2 mg dose. Novo Nordisk projects a regulatory decision from the EU in the first quarter of 2026. The FDA's review, facilitated by the Commissioner's National Priority Voucher (CNPV) expedited program, is anticipated to conclude within one to two months after the agency accepts the filing.

The application for this higher dose is bolstered by robust findings from the STEP UP clinical trial, a 72-week, phase 3 study. This trial rigorously assessed the effectiveness and safety of once-weekly semaglutide 7.2 mg against both a placebo and the established semaglutide 2.4 mg dose in a cohort of 1,407 adults suffering from obesity, explicitly excluding individuals with diabetes. The results showcased a remarkable average weight reduction of 20.7% in patients receiving the 7.2 mg dose, significantly surpassing the 17.5% achieved with the 2.4 mg dose and a mere 2.4% in the placebo group. Furthermore, a substantial 33.2% of participants on the higher dose achieved a weight loss of 25% or more, a notable improvement over the 16.7% for the 2.4 mg dose and zero percent for placebo, highlighting the enhanced efficacy of the new formulation.

This development signifies a promising advancement in the treatment of obesity, offering a more potent option for individuals seeking effective chronic weight management. The positive outcomes from the STEP UP trial underscore the potential of this higher-dose semaglutide to significantly improve health outcomes and quality of life for a broad patient population. The expedited review by regulatory bodies reflects the urgent need and high anticipation for such innovative therapeutic solutions in addressing the global health challenge of obesity.

Analysts Raise Price Targets for Kohl's Following Strong Q3 Performance

Kohl's Corporation (KSS) has recently announced financial results for its third fiscal quarter of 2025 that have exceeded market expectations, leading to an upward revision of price targets by financial analysts. The department store giant posted an adjusted earnings per share of 10 cents, significantly outperforming the consensus analyst forecast which predicted a loss of 20 cents. Furthermore, the company's quarterly revenue stood at $3.41 billion, surpassing the estimated $3.32 billion, despite a modest 1.7% dip in comparable sales. This positive performance has instilled renewed confidence among investors and market observers.

Kohl's Financial Upswing: Q3 Results and Leadership Confirmation

In a recent corporate announcement, Kohl's Corporation revealed its robust financial performance for the third fiscal quarter of 2025, significantly exceeding prior market predictions. The company declared an adjusted earnings per share (EPS) of 10 cents, a remarkable turnaround from the anticipated loss of 20 cents. Furthermore, total revenue for the quarter reached $3.41 billion, comfortably surpassing the $3.32 billion estimated by analysts. Despite a slight decrease of 1.7% in comparable sales, the overall financial health of the company appears to be strengthening.

Michael J. Bender, the Chief Executive Officer, expressed his satisfaction with these results, highlighting them as the third consecutive quarter where the company has surpassed both top-line and bottom-line expectations. Bender emphasized that these achievements are a direct outcome of the strategic initiatives implemented in 2025, bolstering confidence in the company's ongoing trajectory.

Following these positive developments, Kohl's has revised its adjusted EPS guidance for fiscal year 2025 upwards, from a previous range of 50-80 cents to $1.25-$1.45, notably higher than the current consensus estimate of 71 cents. The company projects net sales to experience a decline between 3.5% and 4%.

In a significant leadership decision, the Board of Kohl's Corporation unanimously appointed Michael J. Bender as the permanent CEO, effective November 23, 2025. Bender had been serving as interim CEO since May 1, 2025, and will continue to hold his position on the Board.

In response to the strong earnings report, Kohl's shares saw a substantial increase, closing up 42.5% at $22.42 on Tuesday. This surge prompted several financial analysts to adjust their price targets for Kohl's. Specifically, Evercore ISI Group analyst Michael Binetti maintained an 'In-Line' rating but raised the price target from $13 to $21. Similarly, Telsey Advisory Group analyst Dana Telsey kept a 'Market Perform' rating while increasing the price target from $16 to $23, reflecting the improved outlook for the retail giant.

The impressive third-quarter results and the subsequent positive analyst revisions underscore Kohl's resilience and strategic effectiveness in a competitive retail landscape. The sustained performance, coupled with a confirmed leadership, suggests a promising outlook for the company, potentially attracting further investor interest and solidifying its market position.

See More

Polymarket Traders Divided on Whether GOOGL Stock Can Reach $350 This Year

Alphabet Inc. (GOOGL) is currently experiencing a robust upward trajectory in its stock performance, prompting a split among Polymarket traders regarding its future valuation. While a significant majority believes the stock could reach $335 by 2026, the prospect of hitting $350 remains a point of contention. This optimistic outlook is largely fueled by the company's solid foundational advancements, particularly in large-model artificial intelligence and expanding cloud infrastructure capabilities. The stock's recent movements above critical resistance levels suggest a continued acceleration in its market trend, drawing considerable interest from investors tracking its potential for further growth.

Prediction markets reveal a strong sense of confidence among participants regarding Alphabet's sustained rally. Polymarket data indicates a 90% probability of GOOGL achieving $335 before 2026. Delving deeper, the likelihood of the stock touching $345 is pegged at 65%, with a slightly more cautious 42% chance for it to reach $355 within the same timeframe. These forecasts underscore a prevalent belief in the market that Alphabet's underlying business strengths are poised to drive its stock higher in the coming period.

Alphabet's stock continues to reinforce its breakout structure, maintaining gains near the $323 mark in recent trading sessions. The stock's movement within an ascending channel, which has characterized its rally since late summer, confirms a shift into a more aggressive upward trend. The $313 price point, previously a resistance level, has now transformed into a support zone, indicating a strengthening bullish sentiment. This critical level is expected to act as a safeguard against downward price movements, with buyers likely to step in and defend it should momentum wane.

Analyzing short-term charts further supports the expectation of continued upward momentum. The 30-minute chart shows GOOGL consistently trading above its session Volume Weighted Average Price (VWAP) of approximately $323, with any dips quickly being absorbed by buyers. The formation of higher lows during pullbacks signifies a resilient intraday structure, provided the price remains above $321. Although the Relative Strength Index (RSI) has receded from overbought conditions, it remains above 50, signaling consolidation rather than an impending reversal. This technical setup implies that the stock is pausing to gather strength before potentially resuming its climb.

The positive outlook for Alphabet is significantly bolstered by ongoing advancements in artificial intelligence. Google's recent performance enhancements have solidified its position as a formidable competitor against other major players in the high-capacity computing market. Furthermore, the US government's 'Genesis Mission,' an initiative aimed at broadening access to national supercomputing resources, is expected to stimulate industry-wide demand for advanced AI infrastructure. This program is anticipated to foster increased public-private research collaborations, from which Google Cloud is projected to be a major beneficiary, further fueling its growth prospects.

As Alphabet's stock navigates its current uptrend, bolstered by strong fundamentals and favorable market sentiment, the immediate future holds potential for significant valuation changes. The confluence of technical indicators and strategic business developments suggests that the company is well-positioned for further appreciation, though reaching the $350 mark this year remains a subject of ongoing debate among market observers.

See More